Your browser doesn't support javascript.
Defining the risk of SARS-CoV-2 variants on immune protection.
DeGrace, Marciela M; Ghedin, Elodie; Frieman, Matthew B; Krammer, Florian; Grifoni, Alba; Alisoltani, Arghavan; Alter, Galit; Amara, Rama R; Baric, Ralph S; Barouch, Dan H; Bloom, Jesse D; Bloyet, Louis-Marie; Bonenfant, Gaston; Boon, Adrianus C M; Boritz, Eli A; Bratt, Debbie L; Bricker, Traci L; Brown, Liliana; Buchser, William J; Carreño, Juan Manuel; Cohen-Lavi, Liel; Darling, Tamarand L; Davis-Gardner, Meredith E; Dearlove, Bethany L; Di, Han; Dittmann, Meike; Doria-Rose, Nicole A; Douek, Daniel C; Drosten, Christian; Edara, Venkata-Viswanadh; Ellebedy, Ali; Fabrizio, Thomas P; Ferrari, Guido; Fischer, Will M; Florence, William C; Fouchier, Ron A M; Franks, John; García-Sastre, Adolfo; Godzik, Adam; Gonzalez-Reiche, Ana Silvia; Gordon, Aubree; Haagmans, Bart L; Halfmann, Peter J; Ho, David D; Holbrook, Michael R; Huang, Yaoxing; James, Sarah L; Jaroszewski, Lukasz; Jeevan, Trushar; Johnson, Robert M.
  • DeGrace MM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Ghedin E; Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Frieman MB; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Krammer F; Systems Genomics Section, Laboratory of Parasitic Diseases, National Institutes of Health, Rockville, MD, USA.
  • Grifoni A; Center for Pathogen Research, Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, USA.
  • Alisoltani A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.
  • Alter G; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.
  • Amara RR; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Baric RS; University of California Riverside School of Medicine, Riverside, CA, USA.
  • Barouch DH; Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
  • Bloom JD; Department of Microbiology and Immunology, Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Bloyet LM; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bonenfant G; Department of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Boon ACM; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Boritz EA; Fred Hutch Cancer Center, Howard Hughes Medical Institute, Seattle, WA, USA.
  • Bratt DL; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Bricker TL; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Brown L; Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
  • Buchser WJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Carreño JM; Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Cohen-Lavi L; Vaccine Research Center, Bethesda, MD, USA.
  • Darling TL; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Davis-Gardner ME; Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Dearlove BL; CAMRIS, Contractor for NIAID, Bethesda, MD, USA.
  • Di H; Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
  • Dittmann M; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Doria-Rose NA; Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Douek DC; High Throughput Screening Center, Washington University School of Medicine, St Louis, MO, USA.
  • Drosten C; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Edara VV; National Institute for Biotechnology in the Negev, Department of Industrial Engineering and Management, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
  • Ellebedy A; Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
  • Fabrizio TP; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Ferrari G; US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Fischer WM; CDC COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Florence WC; Microbiology Department, New York University Grossman School of Medicine, New York, NY, USA.
  • Fouchier RAM; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Franks J; Vaccine Research Center, Bethesda, MD, USA.
  • García-Sastre A; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Godzik A; Vaccine Research Center, Bethesda, MD, USA.
  • Gonzalez-Reiche AS; Institute of Virology, Charité-Universitätsmedizin and German Center for Infection Research (DZIF), Berlin, Germany.
  • Gordon A; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Haagmans BL; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Halfmann PJ; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Ho DD; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Holbrook MR; Los Alamos National Laboratory, New Mexico Consortium, Los Alamos, NM, USA.
  • Huang Y; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • James SL; Division of Microbiology and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Jaroszewski L; Department Viroscience, Erasmus MC, Rotterdam, The Netherlands.
  • Jeevan T; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Johnson RM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nature ; 605(7911): 640-652, 2022 05.
Article in English | MEDLINE | ID: covidwho-1773987
ABSTRACT
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Country/Region as subject: North America Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04690-5

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Country/Region as subject: North America Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04690-5